ATHA

Athira Pharma (ATHA)

Athira Pharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ATHA

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/12	20 : 00	GlobeNewswire Inc.	Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients	NASDAQ:ATHA	Athira Pharma Inc
2024/06/11	20 : 00	GlobeNewswire Inc.	Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)	NASDAQ:ATHA	Athira Pharma Inc
2024/05/30	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATHA	Athira Pharma Inc
2024/05/29	20 : 00	GlobeNewswire Inc.	Athira Pharma to Participate in Upcoming June Conferences	NASDAQ:ATHA	Athira Pharma Inc
2024/05/25	08 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATHA	Athira Pharma Inc
2024/05/25	07 : 58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATHA	Athira Pharma Inc
2024/05/25	07 : 56	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATHA	Athira Pharma Inc
2024/05/18	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATHA	Athira Pharma Inc
2024/05/18	06 : 00	GlobeNewswire Inc.	Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action	NASDAQ:ATHA	Athira Pharma Inc
2024/05/16	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATHA	Athira Pharma Inc
2024/05/16	05 : 05	GlobeNewswire Inc.	Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates	NASDAQ:ATHA	Athira Pharma Inc
2024/05/02	20 : 00	GlobeNewswire Inc.	Athira Pharma to Participate in Upcoming May Conferences	NASDAQ:ATHA	Athira Pharma Inc
2024/04/15	20 : 00	GlobeNewswire Inc.	Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer	NASDAQ:ATHA	Athira Pharma Inc
2024/04/11	20 : 00	GlobeNewswire Inc.	Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease	NASDAQ:ATHA	Athira Pharma Inc
2024/04/03	20 : 00	GlobeNewswire Inc.	Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting	NASDAQ:ATHA	Athira Pharma Inc
2024/03/08	21 : 00	GlobeNewswire Inc.	Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference	NASDAQ:ATHA	Athira Pharma Inc
2024/02/23	06 : 34	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ATHA	Athira Pharma Inc
2024/02/23	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATHA	Athira Pharma Inc
2024/02/23	06 : 05	GlobeNewswire Inc.	Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates	NASDAQ:ATHA	Athira Pharma Inc
2024/02/17	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATHA	Athira Pharma Inc
2024/02/17	06 : 54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATHA	Athira Pharma Inc
2024/02/17	06 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATHA	Athira Pharma Inc
2024/02/17	06 : 40	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:ATHA	Athira Pharma Inc
2024/02/17	06 : 37	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:ATHA	Athira Pharma Inc
2024/02/17	06 : 32	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:ATHA	Athira Pharma Inc
2024/02/09	06 : 02	GlobeNewswire Inc.	Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)	NASDAQ:ATHA	Athira Pharma Inc
2024/01/09	06 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATHA	Athira Pharma Inc
2024/01/09	06 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATHA	Athira Pharma Inc
2024/01/09	06 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATHA	Athira Pharma Inc
2024/01/09	06 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATHA	Athira Pharma Inc